Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer

American Journal of Medical Quality

Volumn 17, Issue 6, 2002, Pages 218-224

  Morrow, Thomas ^a,d   Siegel, Michael ^b   Boone, Stanfell ^c   Lawless, Grant ^c   Carter, William ^c  

^a One Health Plan   (United States)

^b AETNA   (United States)

^c AMGEN INC   (United States)

^d NONE   (United States)

Author keywords

Early stage breast cancer; Practice patterns; Quality of care

Indexed keywords

EID: 0040668293     PISSN: 10628606     EISSN: None     Source Type: Journal    
DOI: 10.1177/106286060201700604     Document Type: Article

References (14)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer Statistics. CA Cancer J Clin. 2000;50:7-33.
2. Potosky A, Merrill R, Riley G, et al. Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. J Natl Cancer Inst. 1997;89:1683-1691.
3. Taplin S, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417-426.
4. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2-10.
5. Weiss R, Valagussa P, Moliterni A, et al. Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy: analysis of drug dosing and toxicity. Am J Med. 1987;83:455-463.
6. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320: 491-496.
7. Fisher B, Brown A, Dimitrov N, et al. Two months of doxorubicine-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15. J Clin Oncol. 1990;8:1483-1496.
8. Smalley R, Carpenter J, Bartolucci A, et al. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a southeastern cancer study group project. Cancer. 1977;40:625-632.
9. Bull J, Tormey D, Li S, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978;41:1649-1657.
10. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
11. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205-1211.
12. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-1170.
13. Hryniuk W, Frei E III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16:3137-3147.
14. Link BK, Budd GT, Scott S, et al [for the Oncology Practice Pattern Study Working Group]. Delivering adjuvant chemotherapy to women with early stage breast carcinoma: current patterns of care. Cancer. 2001;92:1354-1367.